Pharmaceutical posts higher net profit at SAR 188.9m in I2 of 2014

30/06/2014 Argaam Exclusive

View other reports

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp (SPIMACO)

Saudi Pharmaceutical Indust.& Med. Appliances Company, the largest pharmaceutical products’ producer in Saudi Arabia, reported SAR 188.9m net profit at the end of the first half of 2014, a 7% increase compared to the same period last year, as shown in the following table:



Financials (M)

Item 6m 2013 6m 2014 Change‬
Revenues 705.59 776.35 10.0 %
Gross Income 363.74 399.87 9.9 %
Operating Income 110.65 120.95 9.3 %
Net Income 176.23 188.88 7.2 %
Average Shares 120.00 120.00 -
EPS (Riyals) 1.47 1.57 7.2 %


Current Quarter Comparison (M)

Compared With The
Item Q2 2013 Q2 2014 Change‬
Revenues 344.22 371.14 7.8 %
Gross Income 179.12 193.14 7.8 %
Operating Income 40.64 44.90 10.5 %
Net Income 113.71 97.72 (14.1 %)
Average Shares 120.00 120.00 -
EPS (Riyals) 0.95 0.81 (14.1 %)


Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2005 166.00 (2.7 %) 74.42 27.2 % 35.38 50.9 % 0.35
Q2 2005 152.77 9.3 % 59.58 8.3 % 24.28 27.7 % 0.24
Q3 2005 141.13 17.6 % 58.99 36.4 % 20.68 51.2 % 0.20
Q4 2005 189.00 24.2 % 78.09 34.8 % 15.80 69.2 % 0.16
Q1 2006 194.37 17.1 % 91.95 23.6 % 37.65 6.4 % 0.37
Q2 2006 185.74 21.6 % 71.43 19.9 % 19.13 (21.2 %) 0.19
Q3 2006 156.57 10.9 % 64.50 9.4 % 23.80 15.1 % 0.23
Q4 2006 191.16 1.1 % 80.54 3.1 % 24.46 54.8 % 0.24
Q1 2007 203.37 4.6 % 91.01 (1.0 %) 39.50 4.9 % 0.39
Q2 2007 209.28 12.7 % 66.46 (7.0 %) 22.57 18.0 % 0.22
Q3 2007 149.40 (4.6 %) 66.84 3.6 % 26.53 11.4 % 0.26
Q4 2007 235.70 23.3 % 102.31 27.0 % 33.28 36.1 % 0.33
Q1 2008 220.58 8.5 % 99.57 9.4 % 40.93 3.6 % 0.40
Q2 2008 211.66 1.1 % 74.78 12.5 % 34.24 51.7 % 0.34
Q3 2008 145.45 (2.6 %) 74.34 11.2 % 15.62 (41.1 %) 0.15
Q4 2008 294.26 24.8 % 114.28 11.7 % 37.48 12.6 % 0.37
Q1 2009 257.88 16.9 % 108.57 9.0 % 42.69 4.3 % 0.42
Q2 2009 229.00 8.2 % 81.53 9.0 % 37.81 10.4 % 0.37
Q3 2009 171.15 17.7 % 72.49 (2.5 %) 15.84 1.4 % 0.16
Q4 2009 292.71 (0.5 %) 157.00 37.4 % 58.48 56.0 % 0.58
Q1 2010 274.33 6.4 % 118.90 9.5 % 45.32 6.2 % 0.38
Q2 2010 252.34 10.2 % 100.50 23.3 % 43.09 14.0 % 0.36
Q3 2010 191.40 11.8 % 85.88 18.5 % 18.07 14.1 % 0.15
Q4 2010 319.57 9.2 % 181.12 15.4 % 70.04 19.8 % 0.58
Q1 2011 252.08 (8.1 %) 123.51 3.9 % 45.71 0.9 % 0.38
Q2 2011 292.08 15.7 % 123.61 23.0 % 60.75 41.0 % 0.51
Q3 2011 209.24 9.3 % 106.76 24.3 % 29.75 64.6 % 0.25
Q4 2011 375.82 17.6 % 206.69 14.1 % 74.06 5.7 % 0.62
Q1 2012 303.14 20.3 % 153.21 24.0 % 56.45 23.5 % 0.47
Q2 2012 286.64 (1.9 %) 140.91 14.0 % 90.14 48.4 % 0.75
Q3 2012 227.40 8.7 % 113.28 6.1 % 32.33 8.7 % 0.27
Q4 2012 365.97 (2.6 %) 211.16 2.2 % 53.73 (27.5 %) 0.45
Q1 2013 361.37 19.2 % 184.62 20.5 % 63.15 11.9 % 0.53
Q2 2013 344.22 20.1 % 179.12 27.1 % 113.71 26.1 % 0.95
Q3 2013 222.91 (2.0 %) 118.64 4.7 % 34.19 5.8 % 0.28
Q4 2013 382.01 4.4 % 226.14 7.1 % 57.01 6.1 % 0.48
Q1 2014 405.21 12.1 % 206.72 12.0 % 91.17 44.4 % 0.76
Q2 2014 371.14 7.8 % 193.14 7.8 % 97.72 (14.1 %) 0.81

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2005 39.90 % 16.36 % 13.40 %
Q2 2005 39.79 % 16.55 % 13.99 %
Q3 2005 40.99 % 17.10 % 14.65 %
Q4 2005 41.77 % 18.97 % 14.82 %
Q1 2006 42.61 % 18.61 % 14.53 %
Q2 2006 42.30 % 18.33 % 13.13 %
Q3 2006 42.16 % 18.23 % 13.28 %
Q4 2006 42.37 % 17.65 % 14.43 %
Q1 2007 41.73 % 17.98 % 14.51 %
Q2 2007 39.78 % 14.82 % 14.51 %
Q3 2007 40.47 % 15.48 % 15.01 %
Q4 2007 40.94 % 15.79 % 15.28 %
Q1 2008 41.13 % 15.70 % 15.13 %
Q2 2008 42.03 % 16.67 % 16.57 %
Q3 2008 43.15 % 16.47 % 15.83 %
Q4 2008 41.63 % 16.30 % 15.25 %
Q1 2009 40.91 % 16.13 % 14.83 %
Q2 2009 40.87 % 16.44 % 14.89 %
Q3 2009 39.57 % 15.73 % 14.07 %
Q4 2009 44.13 % 18.49 % 16.63 %
Q1 2010 44.45 % 18.88 % 16.94 %
Q2 2010 45.32 % 18.93 % 17.07 %
Q3 2010 45.73 % 18.73 % 16.95 %
Q4 2010 46.88 % 18.85 % 17.32 %
Q1 2011 48.36 % 18.99 % 17.42 %
Q2 2011 48.73 % 19.12 % 18.44 %
Q3 2011 49.86 % 19.99 % 19.22 %
Q4 2011 49.64 % 19.57 % 18.62 %
Q1 2012 50.01 % 19.86 % 18.73 %
Q2 2012 51.72 % 20.36 % 21.31 %
Q3 2012 51.47 % 20.54 % 21.21 %
Q4 2012 52.28 % 19.56 % 19.66 %
Q1 2013 52.36 % 19.26 % 19.28 %
Q2 2013 52.98 % 18.87 % 20.24 %
Q3 2013 53.58 % 18.66 % 20.45 %
Q4 2013 54.06 % 18.26 % 20.45 %
Q1 2014 53.95 % 17.92 % 21.86 %
Q2 2014 53.91 % 17.74 % 20.28 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2005 101.51 0.76 0.76 18.03
Q2 2005 101.51 0.81 0.81 18.64
Q3 2005 101.51 0.88 0.88 20.02
Q4 2005 101.51 0.95 0.95 20.18
Q1 2006 101.51 0.97 0.97 25.43
Q2 2006 101.51 0.92 0.92 21.37
Q3 2006 101.51 0.95 0.95 27.26
Q4 2006 101.51 1.03 1.03 19.65
Q1 2007 101.51 1.05 1.05 19.84
Q2 2007 101.51 1.09 1.09 19.42
Q3 2007 101.51 1.11 1.11 21.04
Q4 2007 101.51 1.20 1.20 28.41
Q1 2008 101.51 1.21 1.21 26.83
Q2 2008 101.51 1.33 1.33 27.74
Q3 2008 101.51 1.22 1.27 21.88
Q4 2008 101.51 1.26 1.31 13.76
Q1 2009 101.51 1.28 1.33 14.17
Q2 2009 101.51 1.32 1.36 17.62
Q3 2009 101.51 1.32 1.32 19.72
Q4 2009 101.51 1.53 1.56 21.46
Q1 2010 120.00 1.31 1.36 22.04
Q2 2010 120.00 1.36 1.41 19.98
Q3 2010 120.00 1.37 1.43 21.69
Q4 2010 120.00 1.47 1.50 24.48
Q1 2011 120.00 1.47 1.47 25.41
Q2 2011 120.00 1.62 1.62 27.29
Q3 2011 120.00 1.72 1.72 25.92
Q4 2011 120.00 1.75 1.75 26.50
Q1 2012 120.00 1.84 1.84 30.26
Q2 2012 120.00 2.09 2.09 25.75
Q3 2012 120.00 2.11 2.11 26.24
Q4 2012 120.00 1.94 1.94 25.28
Q1 2013 120.00 1.99 1.99 27.18
Q2 2013 120.00 2.19 2.19 26.14
Q3 2013 120.00 2.21 2.21 27.35
Q4 2013 120.00 2.23 2.23 32.18
Q1 2014 120.00 2.47 2.47 32.96
Q2 2014 120.00 2.33 2.33 33.21

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2005 More than 50 More than 50 2.75
Q2 2005 More than 50 More than 50 4.18
Q3 2005 More than 50 More than 50 4.20
Q4 2005 More than 50 More than 50 6.89
Q1 2006 More than 50 More than 50 4.07
Q2 2006 More than 50 More than 50 4.18
Q3 2006 More than 50 More than 50 3.10
Q4 2006 33.13 33.13 1.74
Q1 2007 30.19 30.19 1.60
Q2 2007 28.33 28.33 1.59
Q3 2007 28.70 28.70 1.52
Q4 2007 33.83 33.83 1.43
Q1 2008 27.68 27.68 1.25
Q2 2008 26.79 26.70 1.28
Q3 2008 20.49 19.74 1.14
Q4 2008 12.99 12.53 1.19
Q1 2009 14.92 14.39 1.35
Q2 2009 17.20 16.65 1.28
Q3 2009 18.29 18.26 1.22
Q4 2009 15.25 14.94 1.08
Q1 2010 16.69 16.04 0.99
Q2 2010 14.70 14.15 1.00
Q3 2010 14.64 14.10 0.93
Q4 2010 15.82 15.53 0.95
Q1 2011 17.65 17.65 1.02
Q2 2011 15.68 15.68 0.93
Q3 2011 14.41 14.41 0.96
Q4 2011 15.03 15.03 0.99
Q1 2012 17.92 17.92 1.09
Q2 2012 12.56 12.56 1.02
Q3 2012 13.70 13.70 1.10
Q4 2012 14.74 14.74 1.13
Q1 2013 13.60 13.60 1.00
Q2 2013 15.51 15.51 1.30
Q3 2013 15.70 15.70 1.27
Q4 2013 19.02 19.02 1.32
Q1 2014 19.07 19.07 1.43
Q2 2014 19.29 19.29 1.36

Business Segments (Million)

Compared With The
Period Medical & Pharmaceutical production segment
Q1 2005 166.00
Q2 2005 152.77
Q3 2005 141.13
Q4 2005 189.00
Q1 2006 194.37
Q2 2006 185.74
Q3 2006 156.57
Q4 2006 191.16
Q1 2007 203.37
Q2 2007 209.28
Q3 2007 149.40
Q4 2007 235.69
Q1 2008 220.58
Q2 2008 211.66
Q3 2008 145.45
Q4 2008 294.25
Q1 2009 257.88
Q2 2009 229.00
Q3 2009 171.15
Q4 2009 292.71
Q1 2010 274.33
Q2 2010 252.34
Q3 2010 191.41
Q4 2010 319.57
Q1 2011 252.08
Q2 2011 292.08
Q3 2011 209.24
Q4 2011 375.82
Q1 2012 303.14
Q2 2012 286.65
Q3 2012 227.40
Q4 2012 365.97
Q1 2013 361.37
Q2 2013 344.22
Q3 2013 222.91
Q4 2013 382.01
Q1 2014 405.21
Q2 2014 374.14

Current
Market Cap (M Riyal) 4,488.00
Enterprise Value (EV) (M) 5,502.21
Shares Outstanding ((M)) 120.00
EPS ( Riyal) (TTM) (0.27)
Book Value (BV) ( Riyal) 12.89
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) Neg
P/E (TTM) NEG
Price/book 2.90
Return on Average Assets (%) (TTM) (0.79 )
Return on Average Equity (%) (TTM) (2.07 )

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.